Extracellular RNAs present in biofluids have emerged as potential biomarkers for disease.
Introduction
Extracellular RNAs (exRNAs) in blood and other biofluids are emerging as potential biomarkers for a wide range of diseases [1] [2] [3] [4] [5] [6] . These so-called liquid biopsies may offer a non-invasive alternative to tissue biopsies for both diagnosis and treatment response monitoring.
To date, the characterization of exRNAs in biofluids has mainly focused on small RNAs in blood derived samples [1] [2] [3] [4] [7] [8] [9] [10] . MicroRNA (miRNA) is the most studied small RNA biotype in biofluids, but other small RNAs, such as piwi-interacting RNAs (piRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), ribosomal RNAs (rRNAs), transfer RNA fragments (tRNAs) and Y-RNAs have also been identified 5, 6, 8, [10] [11] [12] . While most studies have focused on plasma and serum, some groups have investigated the small RNA content of other human biofluids.
Weber et al. 12 was the first to compare the miRNA content in 12 different human biofluids 5, 8, 10, 10, 11 . The distribution of small RNA biotypes clearly varies across these biofluids, with a high abundance of piRNAs and tRNAs reported in urine and a high abundance of Y-RNAs in plasma 6, 8, 11 . Also non-human RNA sequences, mapping to bacterial genomes, were reported in plasma, urine and saliva 6 .
A systematic RNA-sequencing analysis of biofluids to explore the messenger RNAs (mRNA) and circular RNA (circRNA) transcriptome is challenging due to low RNA concentration and RNA fragmentation in biofluids. As such, most studies have explored the abundance of individual mRNAs in one specific biofluid by RT-qPCR [13] [14] [15] [16] [17] [18] [19] . CircRNAs have been reported in saliva 20 , semen 21 , blood 22 and urine 23, 24 . Recently, the mRNA content of plasma and serum has been investigated using dedicated sequencing approaches like Phospho-RNA-Seq and SILVERseq 25, 26 . Studies comparing the small RNA, mRNA and circRNA content in a wide range of human biofluids are currently lacking and are essential to explore the biomarker potential of exRNAs.
The goal of the Human Biofluid RNA Atlas is to define the extracellular transcriptome across a wide range of human biofluids (amniotic fluid, aqueous humor, ascites, bile, bronchial lavage fluid, breast milk, cerebrospinal fluid, colostrum, gastric fluid, pancreatic cyst fluid, plasma, saliva, seminal fluid, serum, sputum, stool, synovial fluid, sweat, tear fluid and urine) and to assess biomarker potential in selected case-control cohorts. We used small RNA-sequencing to quantify different small RNA species and present a dedicated mRNA-capture sequencing workflow to simultaneously quantify mRNAs and circRNAs.
In the first phase of our study, small RNA sequencing and mRNA capture sequencing was performed in a discovery cohort of 20 different biofluids (Fig. 1 ). The goal of this phase was to assess the technical feasibility of the methodology and to generate a comprehensive atlas of mRNAs, circRNAs and small RNAs in which the contributing tissues and cell types per biofluid were assessed.
In the second phase of our study, we aimed to investigate the biomarker potential of exRNAs in various biofluids. Therefore, mRNA capture sequencing was applied to four different case/control cohorts, each consisting of 16-24 samples (Fig. 1 ). These samples included sputum samples from 8 patients with chronic obstructive pulmonary disease (COPD) versus 8 controls, urine samples from 12 bladder cancer patients versus 12 controls, CSF samples from 12 glioblastoma patients versus 12 hydrocephalus patients and saliva samples from 12 diabetes mellitus patients versus 12 controls.
The resulting catalog of extracellular transcriptomes of 180 human samples can guide researchers in the biomarker field to investigate other biofluids besides the well-studied blood-derived ones.
Fig.1 Study flow chart
In the discovery cohort, 20 different biofluids were collected in two donors or in a pool of [4] [5] donors. In the case/control cohorts, selected biofluids (sputum, CSF, urine and saliva) were collected in [8] [9] [10] [11] [12] patients and an equal number of healthy controls. Both small RNA sequencing and mRNA capture sequencing were performed in the discovery cohort. In the case/control cohorts, mRNA capture sequencing was performed. To tissues of origin assessment differential expression GSEA**
Results

RNA spike-in controls enable process control of the RNA sequencing workflow
Synthetic spike-in RNA sequences are crucial to control the process from RNA isolation to RNA sequencing, especially when working with challenging and low input material. We applied 4 different mixes of synthetic RNA spike-in controls (in total 191 RNAs) as workflow processing and normalization controls that enable direct comparison of the RNA profiles across the different biofluids. Sequin and Small RNA extraction Control (RC) spikes were added prior to RNA isolation whereas External RNA Control Consortium (ERCC) spikes and small RNA Library Prep (LP) spikes were added to the RNA eluate prior to genomic DNA (gDNA) removal ( Fig. 1 ).
Of note, every spike mix consists of multiple RNA molecules of different lengths over a wide concentration range. Detailed information is provided in Supplementary Note 1. Besides normalization, the spike-in controls enabled quality control of the RNA extraction and library preparation steps in the workflow and relative quantification of the RNA yield and concentration across the different biofluids.
First, the correlation between the expected and the observed relative quantities for all four spike mixes can be used to assess quantitative linearity. In the discovery cohort, the expected and the observed relative quantities for all four spike mixes were well correlated (Spearman correlation coefficients range from 0.5 to 0.74 for Sequin spikes, 0.92 to 0.99 for ERCC spikes, 0.44 to 0.98 for RC spikes and 0.40 to 0.96 for LP spikes). In some biofluids (e.g. seminal plasma and tears), the sequencing coverage of spikes was low due to a high concentration of endogenous RNA. Detailed information per sample is provided in Supplementary Fig. 1 .
The spike-in controls can also be used to assess the RNA isolation efficiency. The Sequin/ERCC ratio and the RC/LP ratio reflect the relative mRNA and microRNA isolation efficiency,
respectively. An 170-fold and 104-fold difference in RNA isolation efficiency across the samples was observed when assessing long and small RNAs, respectively ( Supplementary Fig.   2 ). These differences underline the challenges of working with heterogenous samples and the importance of spike-in controls for proper data normalization and cross-sample comparison of results.
Finally, the spikes can be utilized to normalize the endogenous RNA abundance data. In this study, we applied a biofluid volume-based normalization by dividing the RNA reads consumed by the endogenous transcripts by the sum of the Sequin spikes for mRNA data and by the sum of the RC spikes for small RNA data. The spike-normalized data represent relative abundance values of RNA molecules proportional to the input volume. Of note, there is an inverse relationship between the number of spike-in RNA reads and the number of endogenous RNA reads. As such, the ratio between the sum of the reads consumed by the endogenous transcripts and the total number of spike-in reads is a relative measure for the RNA concentration of the various samples.
Highly variable mRNA and small RNA content among biofluids in the discovery cohort
Both small RNAs and mRNAs were quantified in each of the 20 biofluids in the discovery cohort. Mapping rates varied substantially across the different biofluids ( Fig. 2A ). In general, the proportion of mapped reads was higher for the mRNA capture sequencing data (further referred to as mRNA data) than for the small RNA sequencing data, in line with the fact that human mRNAs were enriched using biotinylated capture probes during the library preparation. The fraction of mapped reads in the mRNA data ranged from 16% in stool to 97% in seminal plasma. Low mapping rates were observed in stool, in one of the bile samples and in saliva. In the small RNA sequencing data, the proportion of mapped reads ranged from ~7% in stool, saliva and CSF to 95% in platelet-rich plasma (PRP).
A 10 000-fold difference in mRNA and small RNA concentration was observed between the lowest concentrated fluids, i.e. platelet-free plasma, urine and CSF, and the highest concentrated biofluids, i.e. tears, seminal plasma and bile (Fig. 2B ). The mRNA and small RNA concentrations were significantly correlated across biofluids (Spearman correlation coefficient 0.83, p-value = 1.76e-06, Fig. 2D ). Normalized abundance levels of exRNAs were significantly correlated between biological replicates within each biofluid ( Supplementary Fig.   4 ). The median Spearman correlation coefficient of the mRNA and the small RNA data was 0.66 and 0.43, respectively. While the mRNA and small RNA data was well correlated in most biofluids (e.g. tears, colostrum, saliva), correlation in other biofluids (e.g. bile, pancreatic cyst fluid) was poor. These biofluids are obtained with a more challenging collection method involving echo-endoscopy, impacting the reproducibility of collection and the correlation of the RNA content between biological replicates.
The likelihood of identifying RNA biomarkers in a given biofluid will not only depend on its relative RNA concentration, but also on its RNA diversity, here approximated by the fraction of read counts consumed by the top 10 most abundant mRNAs/miRNAs (Fig. 2C ). In aqueous humor, the top 10 mRNAs represent up to 70% of all reads, indicating that this fluid does not contain a rich mRNA repertoire. In both PRP and PPP, about 50% of all reads go to the top 10 mRNAs. While amniotic fluid has a median RNA concentration, this fluid seems to contain a diverse mRNA profile, with only 7% of all reads going to the top 10 mRNAs. When looking into the miRNA data, the top 10 miRNAs represent more than 90% of all reads in PFP, urine and serum. BAL contains the most diverse miRNA repertoire, with 57% of all reads going to the top 10 miRNAs. Similar conclusions with respect to biofluid exRNA diversity can be drawn based on the number of miRNAs/mRNAs representing 50% of the counts ( Supplementary Fig.   3 ). RNA diversity is also reflected by the number of detected exRNAs. The total number of mRNAs and miRNAs detected with at least 4 counts in both samples of the same biofluid ranged from 13 722 mRNAs in pancreatic cyst fluid to 107 mRNAs in aqueous humor and from 231 miRNAs in tears to 18 miRNAs in stool (Table 1) . 
The distribution of small RNA biotypes varies across the different biofluids
The distribution of small RNA biotypes shows distinct patterns among the 20 different biofluids (Fig. 3 ). The exceptionally high percentage of miscellaneous RNAs (mainly Y-RNAs)
observed in blood-derived fluids is in line with a previous study 11 and with the Y-RNA function in platelets. The fraction of reads mapping to miRNAs is lower than 15% in all samples but platelet-free plasma and one synovial fluid sample. Tears, bile and amniotic fluid have the highest fraction of tRNA fragments while saliva has the highest fraction of piRNAs. The rRNA fraction is higher than 15% in all samples but tears, aqueous fluid and the three plasma fractions. The majority of these reads map to the 45S ribosomal RNA transcript. The not annotated read fraction contains uniquely mapped reads that could not be classified in one of the small RNA biotypes. These reads most likely originate from degraded longer RNAs, such as mRNAs and long non-coding RNAs.
Fig. 3 Distinct small RNA biotype patterns are present across the different biofluids
The fraction of reads that align to small RNA biotypes are shown per biofluid. 
Circular RNAs are enriched in biofluids compared to tissues
CircRNAs are produced from unspliced RNA through a process called back-splicing where a downstream 5' donor binds to an upstream 3' acceptor. CircRNAs are resistant to endogenous exonucleases that target free 5' or 3' terminal ends. As a result, circRNAs are highly stable and have extended half-lives compared to linear mRNAs. 27 CircRNAs have been reported to be present in numerous human tissues 23 and in a few biofluids such as saliva 20 , blood 28 , semen 21 and urine 23, 24 . A direct comparison of the circRNA read fraction between biofluids and tissues is currently lacking in literature. We compared the circRNA fraction identified through mRNA capture sequencing of the 20 biofluids in this study with the circRNA fraction identified in mRNA capture sequencing of 36 cancerous tissue types obtained from the MiOncoCirc Database 23 . While more unique backsplice junctions were identified in tissues compared to biofluids, in line with the higher RNA concentration in tissues ( Fig. 4B ), the circRNA read fraction is clearly higher in biofluid exRNA compared to cellular RNA (Fig. 4A ). The median circRNA read fraction in biofluids is 84.4%, which is significantly higher than the median circRNA read fraction in tissues of 17.5% (Mann-Whitney-U test, two-sided, p-value = 5.36 x 10 -12 ). The exRNA in biofluids thus appears primarily derived from stable circRNAs, while the cellular RNA content in tissues is dominated by linear RNAs.
We used two different methods to define the circRNA read fraction (see "Exogenous RNA characterization" in methods; Supplementary Fig. 8 ): one based on individual backsplice junctions (shown in Fig. 4 ) and another method based on backsplice junctions aggregated at gene-level ( Supplementary Fig. 5 ). Both methods clearly point towards a substantial enrichment of circRNAs in biofluids. higher in small RNA sequencing data than in the mRNA data, in line with the unbiased nature of small RNA sequencing and the targeted hybrid capture enrichment using probes against human RNA during the mRNA capture library preparation. Stool (both collection methods), sweat, saliva and sputum are among the biofluids with the highest fraction of bacterial RNA in both the small RNA sequencing data and the mRNA data. The percentage of bacterial reads in mRNA data and in small RNA data are significantly correlated across biofluids (Spearman correlation coefficient 0.81, p-value = 2.20e-16).
Fig. 4 CircRNAs are enriched in biofluids compared to tissues
Bacterial reads in aqueous humor and CSF, two fluids with very low endogenous RNA content that were collected in a sterile setting (and thus presumed to be sterile), most likely reflect background contamination during the workflow 29 . To illustrate the biological relevance of the bacterial signal, we looked into reads mapping to Campylobacter concisus, a gram-negative bacterium that is known to primarily colonize the human oral cavity, with some strains translocated to the intestinal tract 30 . We confirm the selective presence of reads mapping to Campylobacter concisus in saliva in both the small RNA and the mRNA data( Fig. 5B ). In all samples and for both the small RNA and the mRNA data, the percentage of the total reads that maps to viral transcriptomes is less than 1%. 
Assessment of the tissues of origin and deconvolution of pancreatic cyst fluid
Gaining insights in tissue contribution to biofluid RNA profiles may guide the selection of the most appropriate biofluid to investigate a given disease. To define tissues that specifically contribute RNA molecules to individual biofluids, we explored the relationship between extracellular mRNA levels and tissue or cell type specific mRNA signatures. The heatmap in These data strongly suggest that biofluid mRNA levels, at least to some degree, reflect intracellular mRNA levels from cells that produce or transport the fluid. To further investigate the origin of biofluid RNA at the cellular level, we applied computational deconvolution of the pancreatic cyst fluid RNA profiles using single cell RNA sequencing data from 10 pancreatic cell types 31 . Fig. 6B reveals that pancreatic cyst fluid 1 consists of 45% of activated stellate cells and 43% of endothelial cells, while pancreatic cyst fluid 2 mainly consists of quiescent stellate cells (38%), endothelial cells (31%) and acinar cells (19%). compared to healthy controls (Fig. 7B) . CCL20, the most differential mRNA, showed a 146-fold upregulation in COPD patients compared to healthy donors. This potent chemokine attracting dendritic cells has previously been linked to the pathogenesis of COPD 3334 . ADA and MMP1, also among the most differential mRNAs, have also been associated with the pathogenesis of COPD [35] [36] [37] . In contrast to COPD, the relative RNA content is comparable in urine from bladder cancer patients and healthy volunteers, in CSF from glioblastoma patients and hydrocephalus patient, and in saliva from diabetes patients and healthy volunteers ( Fig. 7C/E, Supplementary   Fig. 7 ). In urine from patients with a muscle invaded bladder cancer, 529 mRNAs and 9 mRNAs were significantly upregulated and downregulated, respectively, compared to urine from healthy volunteers (Fig. 7D) . The keratin 5 gene, KRT5, is amongst the upregulated genes in urine from bladder cancer patients compared to healthy volunteers. The presence of KRT5 mRNA in tumor tissue has been studied to subclassify muscle-invasive bladder cancers according to therapy response and patient outcome 38 . In CSF from glioblastoma patients, only 2 mRNAs are significantly upregulated compared to CSF from hydrocephalus patients. CD163, one of the upregulated genes in glioblastoma, has been linked with glioblastoma pathogenesis 39 . In saliva from diabetes patients and saliva from healthy volunteers, no differentially expressed genes could be identified. A list with differentially expressed genes in all case/control cohorts can be found in Supplementary Data 5. previously studied by means of RT-qPCR in amniotic fluid 13 , pancreatic cyst fluid 14, 17 , seminal plasma 15 , sputum 16 , stool 18 and in extracellular vesicles isolated from cell-free urine 19 . In saliva, selected mRNAs were detected using microarrays 40 . We have demonstrated that it is technically feasible to generate mRNA data from low input biofluid samples. This is expected to accelerate biomarker research in these fluids.
Our small RNA results confirm previous studies observing high miRNA concentration in tears 12 , low mapping rates in CSF 5, 41 and low miRNA concentration in cell-free urine 11 .
Aqueous humor and CSF, although collected in a sterile setting and presumed to be sterile, contain up to 11% of reads mapping to bacteria, in line with a previous study 41 Although we collected a broad range of biofluids, only two samples per biofluid were studied, limiting our ability to assess donor variability. The input volume for the RNA isolations in all biofluids was set to 200 µL and a volume-based comparison of the RNA content was made among the biofluids. We did not explore if higher input volumes would result in higher RNA yields in biofluids where this could have been possible (e.g. urine). We also note that the results in Table 1 are impacted by biofluid input volume in the RNA purification, RNA input in the sequencing library prep, and the sequencing depth.
Biofluid data normalization with synthetic spike-in controls is a unique and powerful approach and reflects more accurately the biological situation compared to classic normalization approaches where global differences on overall abundance are neutralized. For instance, the relative mRNA concentration in sputum from COPD patients is higher than in sputum from healthy donors. Typically, RNA sequencing data is subsampled or normalized based on the library size before performing a differential expression analysis, resulting in an artificially more balanced volcano plot, an overcorrection of the biological situation and a loss of information, which is not the case when the data is normalized based on spike-in controls.
Our results highlighting tissues and cell types that contribute more specifically to a certain biofluid compared to the other biofluids ( Fig. 6A) dilemma. Furthermore, pancreatic cysts represent a broad group of lesions, ranging from benign to malignant entities. The main challenge in their management is to accurately predict the malignant potential and to determine the risk to benefit of a surgical resection 44 . Our results show that the cellular contribution to the RNA content of pancreatic cyst fluids can be estimated through deconvolution and that these results may be associated with clinical phenotypes. Larger cohorts are necessary to investigate the clinical potential of this approach and pancreatic tumor cells may also need to be added to the reference set with single cell RNA sequencing data to improve the accuracy of the prediction.
In addition to linear mRNA transcripts, we also explored the circular RNA content in biofluids.
CircRNAs are a growing class of non-coding RNAs and a promising RNA biotype to investigate in the liquid biopsy setting, as they are presumed to be less prone to degradation compared to linear forms 45 . The circRNA fraction in tissues has previously been reported and is in line with our findings 46 . In our study, we clearly demonstrated that circRNAs constitute the main mRNA signal in biofluids.
In conclusion, The Human Biofluid RNA Atlas provides a systematic and comprehensive comparison of the RNA content in 20 different human biofluids and provides a unique glimpse into the extracellular RNA transcriptome from 180 samples. The results presented here may serve as a valuable resource for future biomarker studies.
Material and methods
Donor material, collection and biofluid preparation procedure
Sample collection for the discovery cohort and sputum collection for the case/control cohort was approved by the ethics committee of Ghent University Hospital, Ghent, Belgium (no. Supplementary Table   1 . Detailed information on the sample collection per biofluid is provided in Supplementary Note 2. All samples, except tear fluid, plasma and serum, were centrifuged at 2000 g (rcf) for 10 minutes without brake at room temperature. All samples were processed within 2 hours after collection. The cell-free supernatant was carefully pipetted into 2 mL LoBind tubes (Eppendorf LoBind microcentrifuge tubes, Z666556-250EA) and stored at -80 °C.
RNA isolation and gDNA removal
RNA isolation from all biofluids, except tears
In the discovery cohort, two RNA isolations per biofluid and per sample were simultaneously performed by two researchers (E.V.E. and E.H.). In the end, RNA obtained from both RNA isolations was pooled per biofluid and per sample and this pooled RNA was used as starting material for both library preparations. Hence, small RNA and mRNA capture sequencing on the discovery cohort were performed on the same batch of RNA. In the case/control cohorts, 48 , 1 µl HL-dsDNase and 1.6 µl reaction buffer were added to 12 µl RNA eluate, and incubated for 10 min at 37 °C, followed by 5 min at 55 °C. Per biofluid and per donor the RNA after gDNA removal was pooled. RNA was stored at -80 °C and only thawed on ice immediately before the start of the library prep. Multiple freeze/thaw cycles did not occur.
RNA isolation from tear fluid
Tear fluid was collected in 8 healthy donors with Schirmer strips (2 strips per eye per donor), as previously described 49, 50 
Exogenous RNA characterization
The exogenous RNA content in the mRNA data was assessed using the MetaMap pipeline 51 .
Briefly, all reads were mapped to the human reference genome (hg38) using STAR (v2.5.2) 52 .
Unmapped reads were subsequently subjected to metagenomic classification using CLARK-S (v1.2.3) 53 . Reads were summed across all bacterial species.
The exogenous RNA content in the small RNA data was assessed using the exceRpt small RNAseq pipeline (v4.6.2) in the Genboree workbench with default settings 54 No mismatches were allowed during exogenous alignment. Raw read counts obtained from the Genboree workbench were further analyzed in R (v3.5.1) making use of tidyverse (v1.2.1).
Circular RNA detection and circular/linear ratio determination
Only TruSeq RNA Exome reads passing quality control (base calling accuracy of ≥ 99% in at least 80% of the nucleotides in both mates of a pair) were included in this analysis. Clumpify dedupe (v38.26) was used to remove duplicates in paired-end mode (2 allowed substitutions, kmer size of 31 and 20 passes). We used a two-step mapping strategy to identify forward splice (further referred to as linear) junction reads and backsplice junction reads. First, reads were aligned with TopHat2 (v2.1.0) to the GRCh38/hg38 reference genome (Ensembl, v91).
Micro-exons were included, a minimum anchor length of 6 nucleotides was required, and up to two mismatches in the anchor region were allowed. The resulting output contains linear junction information. Secondly, unmapped reads from the first mapping strategy were realigned with TopHat2 (v2.1.0) to the same reference, but this time with the fusion search option that can align reads to potential fusion transcripts. Processing the fusion search output with CIRCexplorer2 parse (v2.3.3) results in backsplice junction information. Junction read counts obtained with the mapping strategies described above were used as a measure for the relative level of linear and circular RNA in each sample. Only genes with at least one detected backsplice junction were considered. Junctions that could be part of both linear and circular transcripts (ambiguous junctions) were filtered out. As there is currently no consensus on how to calculate the circular to linear ratio (CIRC/LIN), we decided to calculate the ratio in two different ways ( Supplementary Fig. 8 ). The circRNA fraction is defined as 100*CIRC/(CIRC+LIN).
The first method (referred to as "backsplice junction-level method") zooms in on each particular backsplice junction. CIRC was defined as the backsplice junction read count of one particular backsplice junction. LIN was defined as the average read count of all junctions flanking the backsplice junction of interest. The second method (referred to as "gene-level method") considers all backsplice junctions within a given gene. CIRC was defined as the average number of backsplice junction reads for a given gene. LIN was defined as the average number of linear junction reads for a given gene. For both methods, CIRC > 3 was used as a cut-off for filtering noisy backsplice junctions. To enable a comparison of the circular/linear genic ratios in biofluids with those of tissues, the mRNA capture sequencing FASTQ files of 16 cancerous tissue types (34 samples in total) were downloaded from the MiOncoCirc database (dbGaP Study Accession phs000673.v3.p1) 23 . A list with the downloaded samples is attached in Supplementary Table 2 . A table with the read count of backsplice junctions per sample is provided in Supplementary Data 8.
Assessment of tissue and cell contribution to biofluid exRNA
Using total RNA-sequencing data from 27 normal human tissue types and 5 immune cell types from peripheral blood from the RNA Atlas 32 , we created gene sets containing marker genes for each individual entity (Supplementary Data 4). We removed redundant tissues and cell types from the original RNA Atlas (e.g. granulocytes and monocytes were present twice; brain was kept and specific brain sub-regions such as cerebellum, frontal cortex, occipital cortex and parietal cortex were removed) and we used genes where at least one tissue or cell type had expression values greater or equal to 1 TPM normalized counts. A gene was considered to be a marker if its abundance was at least 5 times higher in the most abundant sample compared to the others. For the final analysis, only tissues and cell types with at least 3 markers were included, resulting in 26 tissues and 5 immune cell types.
Gene abundance read counts from the biofluids were normalized using Sequin spikes as size factors in DESeq2 (v1. 22.2) . For all marker genes within each gene set, we computed the log2 fold changes between the median read count of a biofluid sample pair versus the median read count of all other biofluids. The median log2 fold change of all markers in a gene set was selected, followed by z-score transformation over all biofluids (Fig. 7) . For visualization purposes, only tissues and cell types with a z-score ≥ |1| in at least one biofluid were used.
Cellular deconvolution of pancreatic cyst fluid samples
To build the reference matrix for the computational deconvolution of pancreatic cyst fluid samples, single cell RNA sequencing data of 10 pancreatic cell types 31 was processed with the statistical programming language R (v3.6.0). For each gene, the mean count across all individual cells from each cell type was computed. Next, this reference matrix was normalized using the trimmed means of M values (TMM) with the edgeR package (v3.26.4) 5556 . Limmavoom (v3.40.2) 57 was used for subsequent differential gene expression analysis and those genes with an absolute fold change greater or equal to 2 and an adjusted p-value < 0.05 (Benjamini-Hochberg) were retained as markers 58 . Finally, using these markers and both the pancreatic cyst fluid samples and the reference matrix described above, the cell type proportions were obtained through computational deconvolution using non-negative least squares (nnls package; v1.4) 5960 .
Differential expression analysis in case/control cohorts
Further processing of the count tables was done with R (v3.5.1) making use of tidyverse (v1.2.1). Gene expression read counts from the biofluids were normalized using Sequin spikes as size factors in DESeq2 (v1.20.0) 61 . To assess the biological signal in the case/control cohorts, we performed differential expression analysis between the patients and control groups using DESeq2 (v1.20.0). Genes were considered differentially expressed when the absolute log2 fold change > 1 and at q < 0.05.
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